Doccla, a leading provider of virtual ward and remote monitoring technology, has successfully raised £35 million in a Series B funding round. The investment was led by Lakestar, a prominent venture capital firm.
With this new capital infusion, Doccla plans to expand its presence in the European life sciences sector, focusing on markets such as France, Germany, Austria, and Switzerland. This latest funding round comes on the heels of a previous investment of €5 million from Bertelsmann Investments in November 2023.
Founder of Doccla, Martin Ratz, emphasized the benefits of technology-enabled virtual wards for patients, allowing them to recover at home while relieving strain on healthcare providers. He expressed excitement about scaling operations in Europe and investing in data science capabilities.
Doccla’s remote monitoring technology comprises a suite of equipment including a pre-configured tablet and wearable medical devices that can measure vital signs. This solution enables patients to receive care in virtual wards at home, monitored remotely by healthcare professionals, freeing up capacity in traditional care settings.
Lakestar partner and Doccla board member, Oliver Heimes, praised the company’s rapid growth and leadership in the UK market. He highlighted the proven results of remote patient care and its impact on healthcare systems worldwide.
Doccla previously closed a £15 million Series A funding round in September 2022 with support from KHP Ventures, an NHS-founded venture fund. The company also recently partnered with Joined Up Care Derbyshire to implement virtual ward technology across multiple healthcare pathways.
